RCI
TRIL

Ridgeback Capital Investments’s Trillium Therapeutics Inc. TRIL Stock Holding History

Ridgeback Capital Investments’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-370,537
Closed -$4.67M – 3
2015
Q4 		$4.67M Buy
+370,537
New +$5.15M 20.1% 3

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Ridgeback Capital Investments's TRIL Position: Q1 2016 in Review

Ridgeback Capital Investments sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2016, closing a stake of 370,537 shares — an estimated $4.67M sold.

Ridgeback Capital Investments first reported a position in TRIL in Q4 2015 and held it in 1 quarter. The position peaked at $4.67M in Q4 2015. 29 funds tracked by Wall St. Rank hold TRIL as of Q1 2016.

  • Ridgeback Capital Investments reported no remaining Trillium Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
  • Ridgeback Capital Investments sold 370,537 Trillium Therapeutics Inc. shares in Q1 2016, an estimated $4.67M.
  • Ridgeback Capital Investments first reported a position in Trillium Therapeutics Inc. in Q4 2015 and held it in 1 quarter.
  • Ridgeback Capital Investments's Trillium Therapeutics Inc. position peaked at $4.67M in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2016.

Based on Ridgeback Capital Investments's 13F filing for Q1 2016.